Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals director Bruce C. Cozadd reported selling a total of 6,000 ordinary shares of JAZZ in open-market transactions on March 3, 2026. The sales occurred in three blocks at weighted average prices of $186.0853, $186.7340 and $187.8444, executed under a Rule 10b5-1 trading plan. Following these planned sales, Cozadd directly owns 405,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals submitted a Form 144 indicating intended sales of common stock through Merrill Lynch with an associated date of 03/03/2026. The filing lists stock option-related lots dated 11/01/2021 (483 shares), 12/01/2021 (2,952 shares) and 01/03/2022 (2,565 shares).
Jazz Pharmaceuticals director Norbert G. Riedel exercised stock options and sold shares on ordinary shares. On February 27, 2026, he exercised a non-qualified stock option for 3,415 shares, converting it into the same number of ordinary shares at an exercise price of $138.08 per share.
On the same date, he then sold 3,415 ordinary shares in an open-market transaction at $192.00 per share, leaving him with 7,024 ordinary shares held directly. A separate indirect position of 10,630 ordinary shares is reported as held by a trust.
Johnson Philip L reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals executive vice president and chief financial officer Philip L. Johnson reported an equity grant of 11,857 restricted stock units, each representing one ordinary share, awarded at no cash cost under the company’s 2011 Equity Incentive Plan.
The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the next three years. Following this award, Johnson directly holds 62,223 ordinary shares.
Jazz Pharmaceuticals plc executive Samantha Pearce, EVP and Chief Commercial Officer, received an equity award tied to the company’s ordinary shares. She acquired 9,782 restricted stock units, with no cash paid per share, increasing her directly held stake to 52,775 ordinary shares after the transaction.
Each restricted stock unit represents a right to receive one ordinary share if it vests under the company’s 2011 Equity Incentive Plan. The award vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the following three years.
Jazz Pharmaceuticals reported that EVP and Global Head of R&D and CMO Robert Iannone acquired 14,822 ordinary shares through a stock-based award at no cost. The grant consists of restricted stock units that convert into one ordinary share each as they vest.
The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary and the remainder over the following three years. After this award, Iannone directly holds 95,080 ordinary shares.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported a mix of share awards and sales. On February 26, 2026, she received a grant of 2,223 restricted stock units under the company’s 2011 Equity Incentive Plan, with each unit convertible into one ordinary share. These units vest in equal annual installments over four years starting on March 5, 2026.
Also on February 26, 2026, she executed an open-market sale of 1,253 ordinary shares at a weighted average price of $194.1119, in multiple trades between $193.7300 and $194.4100, and shares were sold to satisfy tax obligations from vesting restricted stock units. On February 27, 2026, she sold an additional 1,117 ordinary shares at an average price of $190.9073. After these transactions, she directly held 9,235 ordinary shares.
GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that President & CEO Renee D. Gala received an equity grant of 44,465 restricted stock units under the company’s 2011 Equity Incentive Plan. Each unit represents a right to receive one ordinary share when it vests.
The grant vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remaining three-quarters vesting in equal annual installments over the following three years. After this award, she directly holds 159,695 ordinary shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Ted W. Love reported receiving a grant of 1,527 ordinary shares in the form of restricted stock units. The award was made at a price of $0.00 per share, reflecting an equity compensation grant rather than a market purchase.
Each restricted stock unit represents the right to receive one ordinary share if certain conditions are met. The units are scheduled to vest in full on July 24, 2026, subject to Dr. Love’s continuous service and additional plan conditions. Following this grant, he holds 1,527 ordinary shares directly.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported a mix of stock option exercises, share sales, and equity awards. She exercised multiple incentive and non-qualified stock options into ordinary shares and sold a total of 55,600 ordinary shares in open-market transactions at weighted average prices generally around $190–$193 per share. Patil also acquired 10,079 restricted stock units granted under the 2011 Equity Incentive Plan, which vest in equal annual installments over four years starting on March 5, 2026. Following these transactions, she directly owns 58,818 ordinary shares of Jazz Pharmaceuticals.